Correction: Secondary autoimmune and inflammatory diseases after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT transplant complications and autoimmune diseases working parties - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Amendment: Post-Transplant Autoimmune and Inflammatory Disorders Following Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis by the EBMT Working Groups on Transplant Complications and Autoimmune Conditions

  • By

  • Arsene Mekinian

  • Artem Oganesyan

  • Zinaida Perić

  • Myriam Labopin

  • Urpu Salmenniemi

  • José Antonio Pérez Simón

  • Anke Verlinden

  • Ioanna Sakellari

  • Mohsen Alzahrani

  • Massimo Martino

  • Frédéric Baron

  • John A. Snowden

  • Hakan Ozdogu

  • Alexander Kulagin

  • Edgar Jost

  • Anna Torrent

  • Fabio Benedetti

  • Anna De Becker

  • Sylvie François

  • Montserrat Rovira

  • Hans Christian Reinhardt

  • Alessandra Biffi

  • Mark Ringhoffer

  • Pascal Ambron

  • Jose Luis López Lorenzo

  • Nabil Yafour

  • Alexandre Galvagni

  • Manuela Badoglio

  • Ivan Moiseev

  • Tobias Alexander

  • Mohamad Mohty

  • Olivier Fain

  • Raffaella Greco

  • Olaf Penack

  • September 25, 2026

Share

Clinical Report: Post-Transplant Autoimmune and Inflammatory Disorders Following Allogeneic Hematopoietic Stem Cell Transplantation

Background

Allogeneic hematopoietic stem cell transplantation is a critical intervention for various hematological malignancies, yet it is associated with significant immune-mediated complications. Understanding the occurrence and management of secondary autoimmune and inflammatory diseases post-transplant is essential.

Data Highlights

The original article has undergone correction regarding its title and authorship attribution to accurately reflect the EBMT Complications Working Party.

Key Findings

  • The retrospective study characterizes SAIDs after first allo-HCT performed for hematologic malignancies or severe aplastic anemia.
  • SAIDs are identified as underrecognized complications following allo-HCT.
  • The EBMT Complications Working Party conducted the analysis, emphasizing the need for structured follow-up.
  • Recent EBMT guidelines link alemtuzumab use in conditioning regimens to increased mortality and risk of SAIDs.
  • Multidisciplinary management is crucial for capturing late immune-mediated complications.

Clinical Implications

Healthcare professionals should monitor for SAIDs in patients post-allo-HCT. Incorporating findings from the EBMT guidelines can aid in risk assessment and management strategies.

Conclusion

Recognizing and addressing secondary autoimmune and inflammatory diseases is important in the context of allogeneic hematopoietic stem cell transplantation.

Related Resources & Content

  1. EBMT Complications Working Party, Bone Marrow Transplantation, 2026 -- Secondary autoimmune and inflammatory diseases after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT Complications Working Party (CWP)
  2. Bone Marrow Transplantation, 2026 -- Early high-resolution immune profiles are associated with survival, relapse and graft-versus-host-disease after allogeneic hematopoietic cell transplantation
  3. Bone Marrow Transplantation, 2021 -- Autologous Stem Cell Transplantation in the Management of Post-Transplant Lymphoproliferative Disorders Following Solid Organ Transplantation: A Retrospective Study by the EBMT Lymphoma Working Party
  4. Bone Marrow Transplantation, 2026 -- HLA matching in contemporary haematopoietic cell transplantation: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee
  5. Bone Marrow Transplantation, 2026 -- Evaluation of GvHD Prevention Strategies Utilizing In Vivo T-Cell Depletion (ATG vs. Alemtuzumab) in AML Patients Undergoing Allo-HCT from Unrelated Donors with Intermediate Conditioning Protocols: A Registry Analysis by the EBMT Acute Leukemia Working Group
  6. Bone Marrow Transplantation, 2025 -- Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee
  7. Autoimmune neutropenia: a rare complication of allogeneic hematopoietic stem cell transplantation?, 2023
  8. Secondary autoimmune and inflammatory diseases after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT Complications Working Party (CWP).
  9. Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee | Bone Marrow Transplantation
  10. Autoimmune neutropenia: a rare complication of allogeneic hematopoietic stem cell transplantation?

Original Source(s)

Correction: Secondary autoimmune and inflammatory diseases after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT transplant complications and autoimmune diseases working parties

  • by Arsene Mekinian, Artem Oganesyan, Zinaida Perić, Myriam Labopin, Urpu Salmenniemi, José Antonio Pérez Simón, Anke Verlinden, Ioanna Sakellari, Mohsen Alzahrani, Massimo Martino, Frédéric Baron, John A. Snowden, Hakan Ozdogu, Alexander Kulagin, Edgar Jost, Anna Torrent, Fabio Benedetti, Anna De Becker, Sylvie François, Montserrat Rovira, Hans Christian Reinhardt, Alessandra Biffi, Mark Ringhoffer, Pascal Ambron, Jose Luis López Lorenzo, Nabil Yafour, Alexandre Galvagni, Manuela Badoglio, Ivan Moiseev, Tobias Alexander, Mohamad Mohty, Olivier Fain, Raffaella Greco, Olaf Penack

  • September 25, 2026

Related Content

Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemia

Musings From the Power List: Jason Bock

Jason Bock shares his outlook on RNA-targeting therapies, personalized medicine, and the future of drug development

Publisher Correction: defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from the EBMT global committee